MedTrace Logo

BIBF 1120 for Recurrent High-Grade Gliomas

NCT01380782 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-08-18

Study results available
· View outcomes & findings →

Summary

BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies suggests that this agent, BIBF 1120, may help to stop recurrent malignant glioma cells from multiplying and it may also prevent the growth of new blood vessels at the site of the tumor. In this research study, the investigators are looking to see how well BIBF 1120 works in patients with recurrent malignant gliomas.

Conditions

  • Glioblastoma
  • Gliosarcoma
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Anaplastic Oligoastrocytoma

Interventions

DRUG

BIBF 1120

200 mg BID oral for 28 day cycle

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Wake Forest University Health Sciences

    collaborator OTHER

  • University of Virginia

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • The Cleveland Clinic

    collaborator OTHER

  • Patrick Y. Wen, MD

    lead OTHER

Principal Investigators

  • Patrick Y Wen, M.D. · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380782 on ClinicalTrials.gov